<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03610282</url>
  </required_header>
  <id_info>
    <org_study_id>2018P001421</org_study_id>
    <nct_id>NCT03610282</nct_id>
  </id_info>
  <brief_title>EEG Study of IV Methylphenidate-Induced Emergence From Propofol Sedation</brief_title>
  <official_title>Electroencephalogram Study of Intravenous Methylphenidate-Induced Emergence From Propofol Sedation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are performing this research study to find out if intravenous (IV)
      methylphenidate (commonly known as Ritalin) can help people recover faster from propofol
      sedation. The investigators also want to know how IV methylphenidate acts in the brain and
      whether IV methylphenidate is safe to take with an anesthetic (a drug or agent used to
      decrease or eliminate the feeling of pain by causing unconsciousness) without causing too
      many side effects. The brain's electrical activity will be studied and recorded using a
      machine called an electroencephalogram (EEG).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During this research study, participants will receive propofol, and propofol and IV
      methylphenidate together, at a high enough dose to achieve unconsciousness (make study
      participants &quot;fall asleep&quot;). During one visit participants will receive propofol and a saline
      placebo; during another visit participants will be given both propofol and IV methylphenidate
      together. The investigators will record EEG the entire time, The investigators will also ask
      some questions related to cognitive function.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    We have decided to withdraw the study prior to enrollment of the first participant in order to
    pursue other research studies.
  </why_stopped>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in multitaper spectral estimates of EEG power during a continuous infusion of propofol.</measure>
    <time_frame>Up to 100 minutes</time_frame>
    <description>Change from baseline in multitaper spectral estimates of EEG power associated with the administration of IV methylphenidate.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>EEG Dynamics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EEG data will be collected on patients receiving propofol and IV methylphenidate together.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol EEG Dynamics</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>EEG data will be collected on patients receiving propofol and a saline placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Methylphenidate</intervention_name>
    <description>Subjects will receive a bolus of IV methylphenidate during propofol infusion at one of the study visits.</description>
    <arm_group_label>EEG Dynamics</arm_group_label>
    <other_name>Ritalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Subjects will received propofol for up to 100 minutes.</description>
    <arm_group_label>EEG Dynamics</arm_group_label>
    <arm_group_label>Propofol EEG Dynamics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between the ages of 18 to 45

          -  Normal body weight and habitus, BMI ≤ 30

          -  Non-smoker

          -  No history of taking stimulants

          -  American Society of Anesthesiologists (ASA) physical status classification P1

        Exclusion Criteria:

        • Chronic health conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ken Solt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 26, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Ken Solt</investigator_full_name>
    <investigator_title>MD, Associate Professor of Anaesthesia</investigator_title>
  </responsible_party>
  <keyword>Propofol</keyword>
  <keyword>Methylphenidate</keyword>
  <keyword>Ritalin</keyword>
  <keyword>Anesthetics</keyword>
  <keyword>Anesthetics, Intravenous</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <keyword>Anesthetics, General</keyword>
  <keyword>Neurotransmitter Agents</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

